The Nasopharyngeal Carcinoma and Its Effect on the Infectious Eye Disease: A Nationwide Cohort Study
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Data Source
2.2. Patient Selection
2.3. Main Outcome Measurement
2.4. Demographic and Co-Morbidity Covariates
2.5. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Chua, M.L.K.; Wee, J.T.S.; Hui, E.P.; Chan, A.T.C. Nasopharyngeal carcinoma. Lancet 2016, 387, 1012–1024. [Google Scholar] [CrossRef] [PubMed]
- Chang, E.T.; Ye, W.; Zeng, Y.X.; Adami, H.O. The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol. Biomark. Prev. 2021, 30, 1035–1047. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.P.; Chan, A.T.C.; Le, Q.T.; Blanchard, P.; Sun, Y.; Ma, J. Nasopharyngeal carcinoma. Lancet 2019, 394, 64–80. [Google Scholar] [CrossRef]
- Jeyakumar, A.; Brickman, T.M.; Jeyakumar, A.; Doerr, T. Review of nasopharyngeal carcinoma. Ear. Nose Throat J. 2006, 85, 168–184. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, A.W.M.; Ng, W.T.; Chan, J.Y.W.; Corry, J.; Mäkitie, A.; Mendenhall, W.M.; Rinaldo, A.; Rodrigo, J.P.; Saba, N.F.; Strojan, P.; et al. Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat. Rev. 2019, 79, 101890. [Google Scholar] [CrossRef] [PubMed]
- Caponigro, F.; Longo, F.; Ionna, F.; Perri, F. Treatment approaches to nasopharyngeal carcinoma: A review. Anticancer Drugs 2010, 21, 471–477. [Google Scholar] [CrossRef] [PubMed]
- Yu, B.; Lin, F.; Duan, J.; Ning, H. The influence of marital status on survival in patients with nasopharyngeal carcinoma: A surveillance, epidemiology, and end results database analysis. Medicine 2022, 101, e30516. [Google Scholar] [CrossRef]
- Wu, L.; Li, C.; Pan, L. Nasopharyngeal carcinoma: A review of current updates. Exp. Ther. Med. 2018, 15, 3687–3692. [Google Scholar] [CrossRef] [Green Version]
- Reffai, A.; Mesmoudi, M.; Derkaoui, T.; Ghailani Nourouti, N.; Barakat, A.; Sellal, N.; Mallick, P.; Bennani Mechita, M. Epidemiological Profile and clinicopathological, therapeutic, and prognostic characteristics of nasopharyngeal carcinoma in northern Morocco. Cancer Control 2021, 28, 10732748211050587. [Google Scholar] [CrossRef] [PubMed]
- Hung, S.H.; Chen, P.Y.; Lin, H.C.; Ting, J.; Chung, S.D. Association of rhinosinusitis with nasopharyngeal carcinoma: A population-based study. Laryngoscope 2014, 124, 1515–1520. [Google Scholar] [CrossRef]
- Young, Y.H. Irradiated ears in nasopharyngeal carcinoma survivors: A review. Laryngoscope 2019, 129, 637–642. [Google Scholar] [CrossRef] [PubMed]
- Ku, P.K.; Yuen, E.H.; Cheung, D.M.; Chan, B.Y.; Ahuja, A.; Leung, S.F.; Tong, M.C.; van Hasselt, A. Early swallowing problems in a cohort of patients with nasopharyngeal carcinoma: Symptomatology and videofluoroscopic findings. Laryngoscope 2007, 117, 142–146. [Google Scholar] [CrossRef] [PubMed]
- Liang, K.L.; Jiang, R.S.; Lin, J.C.; Chiu, Y.J.; Shiao, J.Y.; Su, M.C.; Hsin, C.H. Central nervous system infection in patients with postirradiated nasopharyngeal carcinoma: A case-controlled study. Am. J. Rhinol. Allergy 2009, 23, 417–421. [Google Scholar] [CrossRef] [PubMed]
- Hsu, W.M.; Wang, A.G. Nasopharyngeal carcinoma with orbital invasion. Eye 2004, 18, 833–838. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wong, W.M.; Young, S.M.; Amrith, S. Ophthalmic involvement in nasopharyngeal carcinoma. Orbit 2017, 36, 84–90. [Google Scholar] [CrossRef]
- Brook, I. Late side effects of radiation treatment for head and neck cancer. Radiat. Oncol. J. 2020, 38, 84–92. [Google Scholar] [CrossRef]
- Riley, C.A.; Marino, M.J.; Hawkey, N.; Lawlor, C.M.; McCoul, E.D. Sinonasal tract inflammation as a precursor to nasopharyngeal carcinoma: A systematic review and meta-analysis. Otolaryngol. Head Neck Surg. 2016, 154, 810–816. [Google Scholar] [CrossRef]
- Huang, H.; Wu, Y.; Liao, D.; Zhang, H. Quantitative assessment of the association between interleukin-10 promoter gene polymorphisms and nasopharyngeal carcinoma susceptibility. Minerva Med. 2016, 107, 92–100. [Google Scholar]
- Lee, K.Y.; Seah, L.L.; Tow, S.; Cullen, J.F.; Fong, K.S. Nasopharyngeal carcinoma with orbital involvement. Ophthalmic Plast. Reconstr. Surg. 2008, 24, 185–189. [Google Scholar] [CrossRef]
- Zou, L.; Wu, S.; Liu, Y.; Wang, S.; Wen, W.; Liu, H. Surgery option in the management of delayed diplopia after radiation therapy for nasopharyngeal carcinoma. Eur. J. Ophthalmol. 2018, 28, 547–551. [Google Scholar] [CrossRef]
- Wahab, Z.; Tai, E.; Wan Hitam, W.H.; Sonny Teo, K.S. Corticosteroid therapy in optic neuropathy secondary to nasopharyngeal carcinoma. Cureus 2021, 13, e13735. [Google Scholar] [CrossRef] [PubMed]
- Tsirouki, T.; Dastiridou, A.I.; Ibánez Flores, N.; Cerpa, J.C.; Moschos, M.M.; Brazitikos, P.; Androudi, S. Orbital cellulitis. Surv. Ophthalmol. 2018, 63, 534–553. [Google Scholar] [CrossRef] [PubMed]
- Amin, N.; Syed, I.; Osborne, S. Assessment and management of orbital cellulitis. Br. J. Hosp. Med. 2016, 77, 216–220. [Google Scholar] [CrossRef] [PubMed]
- Austin, A.; Lietman, T.; Rose-Nussbaumer, J. Update on the Management of Infectious Keratitis. Ophthalmology 2017, 124, 1678–1689. [Google Scholar] [CrossRef] [PubMed]
- Lakhundi, S.; Siddiqui, R.; Khan, N.A. Pathogenesis of microbial keratitis. Microb. Pathog. 2017, 104, 97–109. [Google Scholar] [CrossRef] [Green Version]
- Ting, D.S.J.; Ho, C.S.; Deshmukh, R.; Said, D.G.; Dua, H.S. Infectious keratitis: An update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance. Eye 2021, 35, 1084–1101. [Google Scholar] [CrossRef]
- Hoarau, G.; Merabet, L.; Brignole-Baudouin, F.; Mizrahi, A.; Borderie, V.; Bouheraoua, N. Moraxella keratitis: Epidemiology and outcomes. Eur. J. Clin. Microbiol. Infect. Dis. 2020, 39, 2317–2325. [Google Scholar] [CrossRef]
- Naik, M.N.; Vasanthapuram, V.H.; Joseph, J.; Murthy, S.I. Microbial keratitis in thyroid eye disease: Clinical features, microbiological profile, and treatment outcome. Ophthalmic Plast. Reconstr. Surg. 2019, 35, 543–548. [Google Scholar] [CrossRef]
- Hung, N.; Kang, E.Y.; Lee, T.W.; Chen, T.H.; Shyu, Y.C.; Sun, C.C. The risks of corneal surface damage in aqueous-deficient dry eye disease: A 17-year population-based study in Taiwan. Am. J. Ophthalmol. 2021, 227, 231–239. [Google Scholar] [CrossRef]
- Leonardi, A.; Flamion, B.; Baudouin, C. Keratitis in dry eye disease and topical ciclosporin A. Ocul. Immunol. Inflamm. 2017, 25, 577–586. [Google Scholar] [CrossRef]
- Lin, K.T.; Lee, S.Y.; Liu, S.C.; Tsao, C.C.; Hsu, S.D.; Chien, W.C.; Chung, C.H.; Chang, W.K.; Chen, Y.W.; Lin, C.S. Risk of ocular complications following radiation therapy in patients with nasopharyngeal carcinoma. Laryngoscope 2020, 130, 1270–1277. [Google Scholar] [CrossRef] [PubMed]
- Shin, S.C.; Hong, S.L.; Lee, C.H.; Cho, K.S. Orbital metastasis as the primary presentation of nasopharyngeal carcinoma. Braz. J. Otorhinolaryngol. 2016, 82, 614–617. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wong, S.J.; Levi, J. Management of pediatric orbital cellulitis: A systematic review. Int. J. Pediatr. Otorhinolaryngol. 2018, 110, 123–129. [Google Scholar] [CrossRef] [PubMed]
- Murphy, C.; Livingstone, I.; Foot, B.; Murgatroyd, H.; MacEwen, C.J. Orbital cellulitis in Scotland: Current incidence, aetiology, management and outcomes. Br. J. Ophthalmol. 2014, 98, 1575–1578. [Google Scholar] [CrossRef] [PubMed]
- Green, M.; Apel, A.; Stapleton, F. Microbial keratitis in a tertiary centre in Queensland, Australia (1999–2015). Clin. Exp. Optom. 2021, 104, 486–490. [Google Scholar] [CrossRef] [PubMed]
- Kim, S.Y.; Kim, S.H.; Yoon, C.H.; Kim, M.K.; Oh, J.Y. Infectious keratitis in patients with ocular Sjögren’s syndrome. Korean J. Ophthalmol. 2022, 36, 407–412. [Google Scholar] [CrossRef]
- Lee, C.Y.; Ho, Y.J.; Sun, C.C.; Lin, H.C.; Hsiao, C.H.; Ma, D.H.; Lai, C.C.; Chen, H.C. Recurrent fungal keratitis and blepharitis caused by aspergillus flavus. Am. J. Trop. Med. Hyg. 2016, 95, 1216–1218. [Google Scholar] [CrossRef] [Green Version]
- Brody-Camp, S.; McCoul, E.D.; Lefante, J.J.; Aslam, R. Socioeconomic status and survival in nasopharyngeal carcinoma: A population-based study. Laryngoscope 2021, 131, 2719–2723. [Google Scholar] [CrossRef]
Characteristics | Non-NPC Group | NPC Group | ASD |
---|---|---|---|
N | 16,736 | 4184 | |
Year of index | 0.0000 | ||
2001–2005 | 8010 (47.86%) | 2020 (48.28%) | |
2006–2010 | 5168 (30.88%) | 1305 (31.19%) | |
2011–2015 | 3558 (21.26%) | 859 (20.53%) | |
Sex | 0.0244 | ||
Female | 5952 (35.56%) | 1537 (36.74%) | |
Male | 10,784 (64.44%) | 2647 (63.26%) | |
Age | 0.0567 | ||
20–30 | 1349 (8.06%) | 326 (7.79%) | |
30–40 | 2914 (17.41%) | 687 (16.42%) | |
40–50 | 4485 (26.80%) | 1100 (26.29%) | |
50–60 | 4363 (26.07%) | 1078 (25.76%) | |
60–70 | 2285 (13.65%) | 607 (14.51%) | |
>70 | 1340 (8.01%) | 386 (9.23%) | |
Urbanization | 0.0367 | ||
Urban | 10,017 (59.85%) | 2483 (59.35%) | |
Sub-urban | 5296 (31.64%) | 1335 (31.91%) | |
Rural | 1423 (8.50%) | 366 (8.75%) | |
Co-morbidities | |||
Hypertension | 3148 (18.81%) | 851 (20.34%) | 0.0386 |
DM | 1567 (9.36%) | 407 (9.73%) | 0.0124 |
Stable CAD | 683 (4.08%) | 210 (5.02%) | 0.0450 |
Hyperlipidemia | 1529 (9.14%) | 424 (10.13%) | 0.0338 |
Cerebrovascular disease | 752 (4.49%) | 201 (4.80%) | 0.0148 |
Allergic respiratory diseases | 1348 (8.05%) | 456 (10.90%) | 0.0972 |
Rheumatic disease | 132 (0.79%) | 46 (1.10%) | 0.0321 |
Allergic otolaryngologic diseases | 398 (2.38%) | 99 (2.37%) | 0.0008 |
Allergic dermatological diseases | 3240 (19.36%) | 843 (20.15%) | 0.0198 |
External eye diseases | 4070 (24.32%) | 1112 (26.58%) | 0.0945 |
Cancer treatment | |||
Chemotherapy | - | 1584 (37.9%) | |
Radiotherapy | |||
Without radiotherapy | - | 2328 (55.6%) | |
With low dose radiotherapy | - | 922 (22.0%) | |
With high dose radiotherapy | - | 934 (22.3%) |
Eye Diseases | Non-NPC Group (N = 16,736) | NPC Group (N = 4184) | p Value |
---|---|---|---|
Infectious keratitis | |||
Person months | 1,584,236 | 352,044 | |
Event | 2185 | 659 | |
Incidence density # (95% CI) | 1.38 (1.32–1.44) | 1.87 (1.73–2.02) | |
Crude HR (95% CI) | Reference | 1.36 (1.25–1.49) * | |
aHR (95% CI) | Reference | 1.29 (1.16–1.39) * | <0.0001 * |
Orbital cellulitis | |||
Person months | 1,727,918 | 394,085 | |
Event | 35 | 19 | |
Incidence density # (95% CI) | 0.02 (0.01–0.03) | 0.05 (0.03–0.08) | |
Crude HR (95% CI) | Reference | 2.38 (1.36–4.16) * | |
aHR (95% CI) | Reference | 2.24 (1.17–3.98) * | 0.0041 * |
Index | aHR (95% CI) | p Value |
---|---|---|
NPC | 1.29 (1.16–1.39) | <0.0001 * |
Year of index (ref = 2001–2005) | ||
2006–2010 | 0.97 (0.88–1.06) | 0.7732 |
2011–2015 | 0.86 (0.72–1.03) | 0.1104 |
Sex (ref = Female) | ||
Male | 0.74 (0.67–0.78) | <0.0001 * |
Age (ref = 30–40) | ||
20–30 | 1.32 (1.11–1.52) | 0.0006 * |
40–50 | 0.99 (0.86–1.15) | 0.8002 |
50–60 | 1.02 (0.94–1.16) | 0.5398 |
60–70 | 0.96 (0.74–1.18) | 0.6521 |
>70 | 0.76 (0.48–1.17) | 0.1944 |
Urbanization (ref = Urban) | ||
Sub-urban | 0.89 (0.74–0.97) | 0.0124 * |
Rural | 0.85 (0.76–1.02) | 0.0505 |
Co-morbidities | ||
Hypertension | 1.00 (0.90–1.10) | 0.9914 |
DM | 1.03 (0.91–1.15) | 0.7342 |
Stable CAD | 0.98 (0.81–1.14) | 0.8645 |
Hyperlipidemia | 1.01 (0.90–1.16) | 0.8477 |
Cerebrovascular disease | 0.85 (0.72–1.06) | 0.2022 |
Allergic respiratory diseases | 1.30 (1.14–1.40) | <0.0001 * |
Rheumatic disease | 1.27 (0.92–1.83) | 0.1168 |
Allergic otolaryngologic diseases | 0.98 (0.76–1.21) | 0.7826 |
Allergic dermatological diseases | 1.22 (1.11–1.32) | <0.0001 * |
External eye diseases | 1.48 (1.22–1.97) | <0.0001 * |
Index | aHR (95% CI) | p Value |
---|---|---|
NPC | 2.24 (1.17–3.98) * | 0.0041 * |
Year of index (ref = 2001–2005) | ||
2006–2010 | 0.97 (0.52–1.87) | 0.9567 |
2011–2015 | 0.30 (0.05–2.01) | 0.2341 |
Sex (ref = Female) | ||
Male | 1.15 (0.69–2.00) | 0.6475 |
Age (ref = 30–40) | ||
20–30 | 0.42 (0.09–1.96) | 0.3198 |
40–50 | 0.92 (0.42–2.09) | 0.9142 |
50–60 | 0.80 (0.30–2.07) | 0.6396 |
60–70 | 0.54 (0.17–1.74) | 0.2980 |
>70 | 0.85 (0.26–3.25) | 0.8777 |
Urbanization (ref = Urban) | ||
Sub-urban | 1.30 (0.74–2.35) | 0.4140 |
Rural | 2.10 (0.87–4.92) | 0.1735 |
Co-morbidities | ||
Hypertension | 1.01 (0.46–2.16) | 0.9768 |
DM | 1.52 (0.70–3.33) | 0.3229 |
Stable CAD | 1.26 (0.40–3.54) | 0.6886 |
Hyperlipidemia | 1.32 (0.54–3.01) | 0.5681 |
Cerebrovascular disease | 0.89 (0.24–3.10) | 0.8826 |
Allergic respiratory diseases | 1.17 (0.56–2.63) | 0.7141 |
Rheumatic disease | 1.65 (0.42–6.02) | 0.9943 |
Allergic otolaryngologic diseases | 0.79 (0.14–5.53) | 0.8642 |
Allergic dermatological diseases | 1.27 (0.69–2.42) | 0.4287 |
External eye disease | 1.34 (0.89–3.69) | 0.0827 |
Infection Eye Diseases | Non-NPC Group (N = 16,736) | NPC without Chemotherapy (N = 2600) | NPC with Chemotherapy (N = 1584) |
---|---|---|---|
Infectious keratitis | |||
Person months | 1,584,236 | 261,309 | 90,735 |
Event | 2185 | 480 | 179 |
Incidence density # (95% CI) | 1.38 (1.32–1.44) | 1.84 (1.68–2.01) | 1.97 (1.70–2.28) |
aHR1 (95% CI) | Reference | 1.33 (1.21–1.47) * | 1.43 (1.23–1.66) * |
aHR2 (95% CI) | 0.75 (0.68–0.83) * | Reference | 1.07 (0.90–1.28) |
Orbital cellulitis | |||
Person months | 1,727,918 | 292,867 | 101,218 |
Event | 35 | 14 | 5 |
Incidence density # (95% CI) | 0.02 (0.01–0.03) | 0.05 (0.03–0.08) | 0.05 (0.02–0.12) |
aHR1 (95% CI) | Reference | 2.36 (1.27–4.39) * | 2.44 (0.96–6.22) |
aHR2 (95% CI) | 0.42 (0.23–0.79) * | Reference | 1.03 (0.37–2.87) |
Infection Eye Diseases | Non-NPC Group (N = 16,736) | NPC without Radiotherapy (N = 2328) | NPC with Low Dose Radiotherapy (N = 922) | NPC with High Dose Radiotherapy (N = 934) |
---|---|---|---|---|
Infectious keratitis | ||||
Person months | 1,584,236 | 229,686 | 71,126 | 51,232 |
Event | 2185 | 442 | 108 | 109 |
Incidence density # (95% CI) | 1.38 (1.32–1.44) | 1.92 (1.75–2.11) | 1.52 (1.26–1.83) | 2.13 (1.76–2.57) |
aHR1 (95% CI) | Reference | 1.40 (1.26–1.55) * | 1.10 (0.91–1.34) | 1.54 (1.27–1.87) * |
aHR2 (95% CI) | 0.72 (0.65–0.79) | Reference | 0.79 (0.64–0.97) | 1.11 (0.90–1.36) |
Orbital cellulitis | ||||
Person months | 1,727,918 | 259,366 | 77,800 | 56,920 |
Event | 35 | 4 | 10 | 5 |
Incidence density # (95% CI) | 0.02 (0.01–0.03) | 0.02 (0.01–0.04) | 0.13 (0.07–0.24) | 0.09 (0.04–0.21) |
aHR1 (95% CI) | Reference | 0.76 (0.27–2.14) | 6.35 (3.14–7.81) * | 4.34 (1.70–8.07) * |
aHR2 (95% CI) | 1.31 (0.47–3.70) | Reference | 8.33 (2.61–10.57) * | 5.67 (1.53–11.21) * |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lee, C.-Y.; Hsieh, M.-J.; Huang, J.-Y.; Hwang, Y.-S.; Chang, C.-K.; Chen, H.-C.; Yang, S.-F. The Nasopharyngeal Carcinoma and Its Effect on the Infectious Eye Disease: A Nationwide Cohort Study. Cancers 2022, 14, 5745. https://doi.org/10.3390/cancers14235745
Lee C-Y, Hsieh M-J, Huang J-Y, Hwang Y-S, Chang C-K, Chen H-C, Yang S-F. The Nasopharyngeal Carcinoma and Its Effect on the Infectious Eye Disease: A Nationwide Cohort Study. Cancers. 2022; 14(23):5745. https://doi.org/10.3390/cancers14235745
Chicago/Turabian StyleLee, Chia-Yi, Ming-Ju Hsieh, Jing-Yang Huang, Yih-Shiou Hwang, Chao-Kai Chang, Hung-Chi Chen, and Shun-Fa Yang. 2022. "The Nasopharyngeal Carcinoma and Its Effect on the Infectious Eye Disease: A Nationwide Cohort Study" Cancers 14, no. 23: 5745. https://doi.org/10.3390/cancers14235745
APA StyleLee, C. -Y., Hsieh, M. -J., Huang, J. -Y., Hwang, Y. -S., Chang, C. -K., Chen, H. -C., & Yang, S. -F. (2022). The Nasopharyngeal Carcinoma and Its Effect on the Infectious Eye Disease: A Nationwide Cohort Study. Cancers, 14(23), 5745. https://doi.org/10.3390/cancers14235745